Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jorge L. Gomez-Mayorga has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outpatient Versus Inpatient Minimally Invasive Adrenalectomy: A Systematic Review and Meta‐Analysis

    by Rafael R. H. Martin, Jorge L. Gomez‐Mayorga, Anastasia K. Bogdanovski, Iman Abedin, Paul A. Bain, Q. Lina Hu‐Bianco, Benjamin C. James

    Objective: Advances in surgical care have allowed the implementation of outpatient protocols across many traditionally inpatient procedures, including adrenal surgery. However, there is an ongoing debate regarding the safety of outpatient minimally invasive adrenalectomy. This study aims to perform a systematic review and meta‐analysis comparing outpatient to inpatient minimally invasive adrenalectomy. Methods: A systematic search for studies comparing outpatient versus inpatient minimally invasive adrenalectomy in September 2023 on Cochrane, EMBASE, Web of Science, and PubMed was performed. Inclusion criteria were studies comparing outpatient to inpatient minimally invasive adrenalectomy for primary adrenal diseases. Exclusion criteria were studies including open adrenalectomy, radiofrequency ablation, and patients with metastasis to the adrenals. Primary outcomes were 30‐day complications and readmissions. Statistical analysis was performed with a random effects model. Results: Five studies comprising 762 outpatient and 15,331 inpatient adrenalectomies met inclusion criteria. Pooled analysis showed no differences in adjusted 30‐day readmission (OR = 0.88; 95% CI 0.27–2.89; p = 0.84; I 2 = 67%) and complication rates (OR = 0.68; 95% CI 0.39–1.18; p = 0.17; I 2 = 32%). Similarly, no statistically significant differences were found for unadjusted outcomes of acute kidney injury, deep vein thrombosis, pneumonia, urinary tract infection, and surgical site infection. Conclusion: Our study demonstrated no differences in outcomes between outpatient and inpatient minimally invasive adrenalectomy. Future studies should address baseline characteristics that render patients more suitable for outpatient protocols and aim to establish comparable groups at baseline through quasi‐experimental methods. Trial Registration: PROSPERO Registration (CRD42023469240)


  • Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases

    by Samuel D. Butensky, Varun V. Bansal, David G. Su, Muhammad Talha Waheed, Andrei Nikiforchin, Jorge L. Gomez‐Mayorga, Elizabeth Olecki, Shannon N. Radomski, Beatrice Sun, Kiran K. Turaga, et al.

    Background: Gastric cancer with synchronous peritoneal metastases is a debilitating disease with limited treatment options. This article describes an update of the 2018 Chicago Consensus guidelines addressing the management of gastric cancer with synchronous peritoneal metastases in line with the most recent evidence.Methods: A clinical management pathway was updated through two rounds of a Delphi consensus to assess agreement levels with pathway blocks. Supporting evidence underwent evaluation using a rapid literature review. Meta‐analyses were performed as appropriate.Results: Overall, the level of evidence in this disease subset was low to moderate. Of 124 participants in the first round, 109 (88%) responded in the second round. Strong consensus (>90%) was achieved in six of eight blocks (75%) in rounds 1 and 2. A multidisciplinary preoperative assessment and diagnostic laparoscopy should be offered to all patients, whereas patients with a high burden of disease or progression should undergo nonsurgical management. Patients with stable/responsive disease and a low peritoneal carcinomatosis index should subsequently be offered treatment with regional therapeutic interventions and cytoreductive surgery. In patients who are cytology‐positive, systemic therapy can be used to convert them to cytology‐negative, with subsequent surgery offered according to the patient's goals of care. Meta‐analysis of observational and randomized control trials revealed a survival benefit with the addition of intraperitoneal chemotherapy to cytoreductive surgery (hazard ratio, 0.52).Conclusions: The consensus‐driven clinical pathway for gastric cancer with synchronous peritoneal metastases offers vital clinical guidance for practitioners. There is a growing body of high‐quality evidence to support management strategies, and future clinical trials are eagerly awaited.


  • Consensus guideline for the management of peritoneal mesothelioma

    by Leanne M. Brown, Sarah G. Wilkins, Varun V. Bansal, David G. Su, Jorge Gomez‐Mayorga, Kiran K. Turaga, Craig G. Gunderson, Byrne Lee, Garrett M. Nash, John L. Hays, et al.

    The treatment of peritoneal mesothelioma (PeM) poses significant challenges because of its rare incidence, heterogeneity, and limited clinical evidence. This commentary describes results from a national consensus aimed at addressing the management of PeM. An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique, which encompassed two rounds of voting. The levels of agreement for various pathway blocks were assessed. Of 101 participants responding in the first round of modified Delphi voting, 95 (94%) responded in the second round. Over 90% consensus was achieved in five of six and six of six pathway blocks in rounds 1 and 2, respectively. Observation was recommended for benign neoplasms, with guidance for interventions in the presence of symptoms or concerning clinicopathological features. For malignant pathology, management was outlined on the basis of a multidisciplinary assessment of patient characteristics, disease histology, and predictive success of medical and surgical interventions. Additional emphasis was placed on multimodal therapy for intermediate‐risk and appropriate high‐risk patients. A rapid review demonstrated the limited availability of data and inconclusive findings regarding optimal systemic therapy timing. There was unanimous support for considering clinical trial enrollment. Given the limited evidence, the consensus‐driven pathway provides essential guidance regarding the management of PeM. To further direct clinical care, additional dedicated research to generate higher quality evidence is needed.


  • Ten years of physician-modified endografts

    by Andrew P. Sanders, Jorge Gomez-Mayorga, Mohit K. Manchella, Nicholas J. Swerdlow, Marc L. Schermerhorn

  • Open Access

    Thyroid Carcinoma Glycoproteins Express Altered N-Glycans with 3-O-Sulfated Galactose Residues

    by Jordan M. Broekhuis, Dongli Lu, Rajindra P. Aryal, Yasuyuki Matsumoto, Lauren E. Pepi, Natalia Chaves, Jorge L. Gomez-Mayorga, Benjamin C. James, Richard D. Cummings

    Aberrant protein glycosylation is a hallmark alteration of cancer and is highly associated with cancer progression. Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, but the N-glycosylation of its glycoproteins has not been well characterized. In this work, we analyzed multiple freshly prepared PTC specimens along with paired normal tissue obtained from thyroidectomies. Glycomic analyses focused on Asn-linked (N)-glycans and employed mass spectrometry (MS), along with Western blot approaches of total solubilized materials that were examined for binding by specific lectins and a monoclonal antibody (mAb) O6, specific for 3-O-sulfated galactose residues. We observed major differences in PTC versus paired normal specimens, as PTC specimens exhibited higher levels of N-glycan branching and bisection with N-acetylglucosamine residues, consistent with RNAseq data. We also found that 3-O-sulfated galactose was present in N-glycans of multiple glycoproteins from both PTC and control specimens, as recognized by the O6 mAb and as confirmed by MS analyses. These results provide new insights into the N-glycans present in glycoproteins of thyroid cancer and context for further studies of these altered glycans as biomarkers and targets for therapeutics.


  • Outcomes of carotid revascularization stratified by procedure in patients with an estimated glomerular filtration rate of <30 and dialysis patients

    by Elisa Caron, Sai Divya Yadavalli, Mohit Manchella, Gabriel Jabbour, Tim J. Mandigers, Jorge L. Gomez-Mayorga, Randall A. Bloch, Roger B. Davis, Grace J. Wang, Brian A. Nolan, et al.

  • National registry insights on genetic aortopathies and thoracic endovascular aortic interventions

    by Jorge L. Gomez-Mayorga, Sai Divya Yadavalli, Sara Allievi, Sophie X. Wang, Vinamr Rastogi, Sabrina Straus, Tim J. Mandigers, James H. Black, Sara L. Zettervall, Marc L. Schermerhorn

  • Factors associated with nonhome discharge after endovascular aneurysm repair

    by Sabrina Straus, Jorge L. Gomez-Mayorga, Andrew P. Sanders, Sai Divya Yadavalli, Sara Allievi, Katharine L. McGinigle, Lars Stangenberg, Marc Schermerhorn


  • Ten years of physician-modified endografts

    by Andrew P. Sanders, Jorge Gomez-Mayorga, Mohit K. Manchella, Nicholas J. Swerdlow, Marc L. Schermerhorn


  • Outcomes of carotid revascularization stratified by procedure in patients with an estimated glomerular filtration rate of <30 and dialysis patients

    by Elisa Caron, Sai Divya Yadavalli, Mohit Manchella, Gabriel Jabbour, Tim J. Mandigers, Jorge L. Gomez-Mayorga, Randall A. Bloch, Roger B. Davis, Grace J. Wang, Brian A. Nolan, et al.